Recently, we have experienced cerebrovascular embolic events in 2 consecutive patients in our outpatient clinic. Accordingly, we want to share our comments with literature on these 2 patients. Both patients had newly diagnosed left ventricular (LV) dysfunction, sinus rhythm, and cerebrovascular event within the first week after initiation of heart failure treatment. Although, our cases are not enough to make a general statement or conclusion, we can recommend that patients with newly diagnosed severe LV dysfunction with normal sinus rhythm and without echocardiographically visible thrombus should also be closely followed up for thromboembolic complications at least during the first weeks of congestive heart failure treatment.
Introduction
One of the most hazardous complications of heart failure or dilated cardiomyopathy is cerebrovascular embolic events. Fuster et al 1 in a retrospective study of 104 patients with dilated cardiomyopathy has reported an 18% frequency of thromboembolic events in patients not taking warfarin and an incidence of 4 clinically apparent events per 100 patient years. More recent studies reported a lower incidence of thromboembolic events ranging from 1.7/100 to 3.2/100 patient years in patients with severe left ventricular (LV) dysfunction. 2, 3 Today, there is no generally accepted consensus on anticoagulant treatment of patients with severe LV dysfunction and sinus rhythm and without LV thrombus. Recently, we have experienced cerebrovascular embolic events in 2 consecutive patients in our outpatient clinic. Accordingly, we want to share our comments with literature on these 2 patients.
Case 1
A 61-year-old patient presented with the complaints of new onset tiredness, dyspnea, lasting for 3 weeks. His New York Heart Association (NYHA) functional capacity was class III. His physical examination revealed that blood pressure was 130/90 mm Hg, hear rate, 87/min, first and second heard sounds were normal with an apical 2/6 systolic murmur and there was no carotid bruits. There were bilateral rales at the basal segments of the lungs, and neck vein distension was positive. Electrocardiography showed normal sinus rhythm with interventricular conduction defects. Echocardiographic examination revealed dilated cardiomyopathy with an end-diastolic diameter of 6.2 cm and ejection fraction of 25%, without thrombus. Patient was given to congestive heart failure treatment including diuretics, angiotensinconverting enzyme inhibitors, digoxin, b-blockers, and acetylsalicyclic acid (300 mg/d). At the fourth day of heart failure treatment, the patient suffered from aphasia attack lasting 2 hours. He had no history of cerebrovascular events. His serial cerebral computerized tomography imaging did not reveal any acute infarction. Following this observation, patients were administered anticoagulant therapy with warfarin.
Case 2
A 54-year-old man was examined with the complaints of dyspnea lasting for 2 weeks in our outpatient clinic. He was pale and dyspneic on his physical examination. Heart rate was 85/min, jugular neck vein distension was positive, and there were rales up to mid-zone lung segments and S3 on his cardiac auscultation. In addition, there was no carotid bruits. Electrocardiogram revealed sinus rhythm with precordial T-wave changes and interventricular conduction defects. Echocardiographic examination revealed an ejection fraction of 25% and LV dilatation (end-diastolic diameter: 6.6 cm), without LV or atrial thrombus. After a short period of hospitalization to relieve the patient's symptoms, patient was discharged with medical treatment for congestive heart failure (diuretics, angiotensin-converting enzyme inhibitors, digoxin, nitrate, acetylsalicyclic acid [300 mg/d], and subsequently b-blockers), without anticoagulant therapy and he was scheduled to coronary angiography. On the second day of medical treatment, the patient was hospitalized with the complaints of speech disturbances, disturbed consciousness, and left hemiparesis. He had no past history of cerebrovascular event. His diffusion weighted magnetic resonance imaging revealed acute infarction in the right hemisphere. As a measure of precaution against acute vascular events, patients were administered with anticoagulants.
Discussion
There are several critical common points in our cases. Both patients had newly diagnosed LV dysfunction, sinus rhythm, and cerebrovascular event within the first week after initiation of heart failure treatment. Additionally, they had no echocardiographically visible LV thrombus. Before discussing the thromboembolic events occurring immediately after initiation of heart failure treatment, we have to state that this might have happened coincidentally or we might have also missed the diagnosis of LV thrombus by echocardiography or transient atrial fibrillation attack, in both patients presented. However, under the current indefinite knowledge of oral anticoagulant treatment in patients with severe LV dysfunction with normal sinus rhythm and without LV thrombus, our observations on these patients may bring new insights to discuss anticoagulant treatment in those patients.
A poorly contracting ventricle allows blood stasis that can lead to thrombus formation and subsequent embolization. Even without gross thrombus formation, these regional blood flow disturbances could lead to an increase in platelet adhesion due to prolonged residence time of platelets in the cardiac chambers. 4 The incidence of LV thrombus in patients with cardiomyopathy has been reported in the literature 1, [5] [6] [7] as 11% to 44%. The clinical importance of LV thrombus lies in its potential to embolize. At least 11% of patients with dilated cardiomyopathy have one or more embolic events during the course of their illness. 8 Left ventricular thrombus has been defined as an echo-dense mass with a margin distinct from the LV wall, within the LV cavity and is visible throughout the cardiac cycle in at least 2 different echocardiographic views. 9 However, echocardiographically invisible thrombus formation may also occur in the LV cavity. Roberts et al 6 has demonstrated that even in the absence of LV thrombi by echocardiography, it is possible that mural endocardial plaques, most likely resulting from organized thrombi in 25% of patients with dilated cardiomyopathy, may exist in left ventricle. Additionally, comparably increased platelet and coagulation activation has been demonstrated in patients with and without LV thrombus compared to normal participants, indicating patients without LV thrombus carries risk for thromboembolism in terms of platelet and coagulation activation. 10 In spite of the hemodynamical and clinical improvement in patients with severe LV dysfunction, manifestation of cerebrovascular event is an unexpected and unpleasant complication.
Beside the coincidental embolization risk of echocardiographically invisible or visible LV thrombus, relative improvement in LV contraction, preload and after load reduction, and relative decrease of end-diastolic LV pressure might have facilitated the release of freshly formed small thrombi from the LV or less likely from the left atrial cavity. These local hemodynamic changes in left ventricular cavity may lead to freshly formed microthrombus to detach easily from the endocardium, resulting in thromboembolic events.
Based on current evidence, patients with heart failure with poor cardiac function or idiopathic dilated cardiomyopathy, mobile LV thrombus on cardiac imaging are probably at highest risk, requiring anticoagulant therapy. 11 Currently, in literature the only clear-cut indications for anticoagulation in most patients with dilated cardiomyopathy are atrial fibrillation, a previous thromboembolic event, or LV thrombus.
Although our cases are not enough to make a general statement or conclusion, we can recommend that patients with newly diagnosed severe LV dysfunction with normal sinus rhythm and without echocardiographically visible thrombus should also be closely followed up for thromboembolic complications at least during the first weeks of congestive heart failure treatment.
